ALDEYRA THERAPEUTICS, INC. (ALDX) Operating cash flow 2016–2025
ALDEYRA THERAPEUTICS, INC. (ALDX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$33.3MFY2025 · since FY2016: -$15.1M → -$33.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$33.3M | +22.8% |
| FY2024 | -$43.2M | -42.5% |
| FY2023 | -$30.3M | +46.5% |
| FY2022 | -$56.6M | -33.1% |
| FY2021 | -$42.6M | -13.5% |
| FY2020 | -$37.5M | +16.7% |
| FY2019 | -$45.0M | -50.7% |
| FY2018 | -$29.9M | -55.3% |
| FY2017 | -$19.2M | -26.9% |
| FY2016 | -$15.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALDX financial trends
ALDX RevenueALDX Net incomeALDX Net marginALDX Gross profitALDX Gross marginALDX Operating incomeALDX Operating marginALDX Free cash flowALDX Capital expendituresALDX Return on equityALDX Stock buybacksALDX Dividends paidALDX Total assetsALDX Total liabilitiesALDX Shareholders’ equityALDX overview →